Foghorn Therapeutics (FHTX) News Today → The A.I. story nobody is telling you (Read ASAP) (From TradeSmith) (Ad) Free FHTX Stock Alerts $5.67 +0.11 (+1.98%) (As of 05/13/2024 ET) Add Compare Share Share HeadlinesStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial MediaStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial Media All Sources Trusted Sources MarketBeat.com Benzinga Bloomberg MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha The Street The Wall Street Journal Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative May 10 at 3:00 AM | americanbankingnews.comHC Wainwright Weighs in on Foghorn Therapeutics Inc.'s Q3 2024 Earnings (NASDAQ:FHTX)May 10 at 2:16 AM | americanbankingnews.comQ2 2024 EPS Estimates for Foghorn Therapeutics Inc. Increased by Analyst (NASDAQ:FHTX)May 9, 2024 | finance.yahoo.comFoghorn Therapeutics Inc. (NASDAQ:FHTX) Just Reported, And Analysts Assigned A US$11.67 Price TargetMay 9, 2024 | marketbeat.comHC Wainwright Analysts Decrease Earnings Estimates for Foghorn Therapeutics Inc. (NASDAQ:FHTX)Foghorn Therapeutics Inc. (NASDAQ:FHTX - Free Report) - Equities research analysts at HC Wainwright cut their Q3 2024 earnings per share estimates for shares of Foghorn Therapeutics in a report released on Tuesday, May 7th. HC Wainwright analyst A. Fein now anticipates that the company will earnMay 9, 2024 | americanbankingnews.comBrokers Issue Forecasts for Foghorn Therapeutics Inc.'s Q1 2025 Earnings (NASDAQ:FHTX)May 8, 2024 | marketbeat.comBrokers Offer Predictions for Foghorn Therapeutics Inc.'s Q1 2025 Earnings (NASDAQ:FHTX)Foghorn Therapeutics Inc. (NASDAQ:FHTX - Free Report) - Research analysts at Wedbush issued their Q1 2025 earnings estimates for shares of Foghorn Therapeutics in a report released on Monday, May 6th. Wedbush analyst R. Driscoll anticipates that the company will post earnings per share of ($0.36)May 8, 2024 | americanbankingnews.comFoghorn Therapeutics (NASDAQ:FHTX) Receives "Buy" Rating from HC WainwrightMay 7, 2024 | markets.businessinsider.comBuy Rating Affirmed on Foghorn Therapeutics with Promising AML Drug Pipeline and Broad Market PotentialMay 7, 2024 | finance.yahoo.comFoghorn Therapeutics First Quarter 2024 Earnings: EPS Beats Expectations, Revenues LagMay 7, 2024 | marketbeat.comFoghorn Therapeutics' (FHTX) "Buy" Rating Reiterated at HC WainwrightHC Wainwright restated a "buy" rating and set a $20.00 target price on shares of Foghorn Therapeutics in a research report on Tuesday.May 6, 2024 | finanznachrichten.deFoghorn Therapeutics, Inc.: Foghorn Therapeutics Provides First Quarter 2024 Financial and Corporate UpdateMay 6, 2024 | finance.yahoo.comFoghorn Therapeutics Q1 2024 Earnings: Misses Analyst Revenue Projections Amidst Strategic ...May 6, 2024 | investorplace.comFHTX Stock Earnings: Foghorn Therapeutics Beats EPS, Misses Revenue for Q1 2024May 6, 2024 | globenewswire.comFoghorn Therapeutics Provides First Quarter 2024 Financial and Corporate UpdateMay 4, 2024 | americanbankingnews.comHC Wainwright Reaffirms "Buy" Rating for Foghorn Therapeutics (NASDAQ:FHTX)May 1, 2024 | marketbeat.comHC Wainwright Reiterates "Buy" Rating for Foghorn Therapeutics (NASDAQ:FHTX)HC Wainwright reaffirmed a "buy" rating and set a $20.00 target price on shares of Foghorn Therapeutics in a report on Wednesday.April 18, 2024 | bizjournals.comPetri Dish: Non-viral vector startup launch; Foghorn’s new CFOApril 16, 2024 | marketwatch.comFoghorn Therapeutics Taps Kristian Humer as Finance ChiefApril 16, 2024 | globenewswire.comFoghorn Therapeutics Strengthens Financial Leadership with Appointment of Kristian Humer as Chief Financial OfficerApril 10, 2024 | markets.businessinsider.comAnalysts Are Bullish on These Healthcare Stocks: Generation Bio (GBIO), Poseida Therapeutics (PSTX)April 10, 2024 | markets.businessinsider.comFoghorn Therapeutics: Buy Rating Affirmed Amidst Promising Pipeline and Strategic AlliancesApril 10, 2024 | marketbeat.comFoghorn Therapeutics' (FHTX) Outperform Rating Reiterated at WedbushWedbush reissued an "outperform" rating and issued a $13.00 target price on shares of Foghorn Therapeutics in a report on Wednesday.April 9, 2024 | globenewswire.comFoghorn Therapeutics Presents New Preclinical Data on Potential First-in-Class BRM Selective Inhibitor FHD-909 and Selective CBP and Selective EP300 Degrader Oncology ProgramsApril 9, 2024 | finance.yahoo.comFoghorn Therapeutics (NASDAQ:FHTX) Is In A Good Position To Deliver On Growth PlansApril 5, 2024 | finance.yahoo.comFoghorn Therapeutics to Participate in Needham’s 23rd Annual Virtual Healthcare ConferenceApril 5, 2024 | globenewswire.comFoghorn Therapeutics to Participate in Needham's 23rd Annual Virtual Healthcare ConferenceApril 4, 2024 | finance.yahoo.comFed commentary, jobless claims data: What to WatchApril 4, 2024 | marketbeat.comRaymond James & Associates Increases Position in Foghorn Therapeutics Inc. (NASDAQ:FHTX)Raymond James & Associates lifted its holdings in Foghorn Therapeutics Inc. (NASDAQ:FHTX - Free Report) by 45.0% during the 4th quarter, according to the company in its most recent Form 13F filing with the SEC. The firm owned 2,068,387 shares of the company's stock after buying an additional 642,16March 26, 2024 | globenewswire.comFoghorn to Host Conference Call and Webcast on Pipeline of Potential First-in-Class Medicines in Conjunction with the 2024 AACR Annual MeetingMarch 19, 2024 | marketbeat.comFoghorn Therapeutics Inc. (NASDAQ:FHTX) Short Interest Down 8.8% in FebruaryFoghorn Therapeutics Inc. (NASDAQ:FHTX - Get Free Report) saw a significant decline in short interest in the month of February. As of February 29th, there was short interest totalling 1,250,000 shares, a decline of 8.8% from the February 14th total of 1,370,000 shares. Based on an average daily trading volume, of 167,600 shares, the days-to-cover ratio is currently 7.5 days. Currently, 6.8% of the company's shares are short sold.March 8, 2024 | bizjournals.comCambridge biotech discloses it quietly laid off 28% of its staff last yearMarch 7, 2024 | investorplace.comFHTX Stock Earnings: Foghorn Therapeutics Beats EPS, Beats Revenue for Q4 2023March 7, 2024 | benzinga.comFoghorn Therapeutics: Q4 Earnings InsightsMarch 7, 2024 | finanznachrichten.deFoghorn Therapeutics, Inc.: Foghorn Therapeutics Provides Financial Update for 2023 and 2024 Strategic OutlookMarch 7, 2024 | globenewswire.comFoghorn Therapeutics Provides Financial Update for 2023 and 2024 Strategic OutlookMarch 5, 2024 | globenewswire.comFoghorn Therapeutics to Present New Preclinical Data at 2024 AACR Annual Meeting, Reflecting Advances with Multiple Potential First-in-Class Medicines, including the Selective Inhibitor of BRM, FHD-909February 28, 2024 | finance.yahoo.comFoghorn Therapeutics to Participate in Cowen’s 44th Annual Health Care ConferenceFebruary 28, 2024 | globenewswire.comFoghorn Therapeutics to Participate in Cowen's 44th Annual Health Care ConferenceFebruary 26, 2024 | thestreet.comFoghorn Therapeutics Inc.February 16, 2024 | marketbeat.comShort Interest in Foghorn Therapeutics Inc. (NASDAQ:FHTX) Rises By 16.2%Foghorn Therapeutics Inc. (NASDAQ:FHTX - Get Free Report) was the target of a significant growth in short interest in the month of January. As of January 31st, there was short interest totalling 1,060,000 shares, a growth of 16.2% from the January 15th total of 912,600 shares. Approximately 6.0% of the company's shares are sold short. Based on an average daily trading volume, of 137,300 shares, the short-interest ratio is presently 7.7 days.February 15, 2024 | investing.comFoghorn Therapeutics Inc (FHTX)February 12, 2024 | finance.yahoo.comFoghorn Therapeutics Inc. (FHTX) Moves 22.7% Higher: Will This Strength Last?February 9, 2024 | markets.businessinsider.comAnalysts Are Bullish on Top Healthcare Stocks: Foghorn Therapeutics (FHTX), Sensus Healthcare (SRTS)February 9, 2024 | finance.yahoo.comFoghorn (FHTX) Jumps 55% as Lilly Takes Up FHD-909 DevelopmentFebruary 9, 2024 | msn.comFoghorn Therapeutics Releases New Investor PresentationFebruary 8, 2024 | msn.comWhy Foghorn Therapeutics (FHTX) Stock Is Exploding HigherFebruary 8, 2024 | msn.comFoghorn says Eli Lilly picked lung cancer candidate for further studiesFebruary 8, 2024 | finance.yahoo.comFoghorn Provides Pipeline Update on FHD-909 BRM Selective InhibitorJanuary 17, 2024 | marketbeat.comRaymond James & Associates Purchases 235,237 Shares of Foghorn Therapeutics Inc. (NASDAQ:FHTX)Raymond James & Associates increased its position in Foghorn Therapeutics Inc. (NASDAQ:FHTX - Free Report) by 19.8% during the third quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 1,426,226 shares of tJanuary 11, 2024 | finance.yahoo.comWith 39% stake, Foghorn Therapeutics Inc. (NASDAQ:FHTX) seems to have captured institutional investors' interest Get Foghorn Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for FHTX and its competitors with MarketBeat's FREE daily newsletter. Email Address Bill Clinton Backing Biden Replacement??? (Ad)Bill Clinton is back. And he just met in Mexico with the one person I believe could REPLACE Joe Biden by August… Click here now for my urgent election forecast. FHTX Media Mentions By Week FHTX Media SentimentLearn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. FHTX News Sentiment▼0.210.57▲Average Medical News Sentiment FHTX News CoverageLearn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. FHTX Articles This Week▼252▲FHTX Articles Average Week Get Foghorn Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for FHTX and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies: 23andMe News Today Veru News Today Conduit Pharmaceuticals News Today AC Immune News Today Aldeyra Therapeutics News Today Werewolf Therapeutics News Today Emergent BioSolutions News Today Puma Biotechnology News Today Zevra Therapeutics News Today 2seventy bio News Today Headlines Tools: Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:FHTX) was last updated on 5/13/2024 by MarketBeat.com Staff From Our PartnersThe A.I. story nobody is telling you (Read ASAP)TradeSmithThe 2024 Gold Rush: Unleashing Market PotentialPriority GoldHe Is Giving Away BitcoinCrypto Swap ProfitsConflict In Israel Sends Gold Soaring ???? Here’s How To Get Your ShareColonial MetalsGold Set to EXPLODE!Gold Safe ExchangeThe Crypto 9-5 Escape PlanCrypto 101 MediaForget Bitcoin. Crypto Millionaire Predicts 8,788% Gains For THISParadigm PressHow Biden has already won 2024Porter & Company Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Foghorn Therapeutics Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
